This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Fibrocell Science

I wrote a story this week on Derma Sciences (DSCI - Get Report) and its wound-healing drug DSC127, to which Zach P. comments:

"I've been following this one since the phase II data were first released and saw your tweet this morning. At an enterprise value under $75 million, priced much too heavy a discount. I wouldn't argue that the Shire/Advanced BioHealing deal is the perfect proxy given an FDA approved product, sales, etc., but pricing Derma Sciences at one-tenth the value for a product that could generate $150 million with better margins than Dermagraft is ridiculous. Derma Sciences could double and still not be over-valued."

The tweet Zach refers to was actually a retweet of a point made by @sharkbiotech. "Re: $DSCI they have no cash to do a phase III trial. Gonna have to raise cash although they could do that by partnering ex-U.S."

Derma Sciences does a $50 million shelf registered with the SEC so the company could sell stock to raise the money necessary to fund the phase III studies of DSC127. Or, the company could try to fund the studies by selling marketing rights to the drug. Even if Derma sold more stock today, the enterprise value is still relatively low. I agree with Zach on that point.

More from Twitter, @ReformedBroker asks, "How long has Genta(GNTA) been flogging this antisense nonsense? 12 years?"

The two most disappointed men in America this week had to be Harold Camping and Ray Warrell.

Camping, of course didn't get his Rapture last weekend. Warrell, the longtime CEO of the biotech firm Genta, finally had to admit that his decade-long quixotic effort to develop an experimental cancer drug known as Genasense had finally come to an end.

Genta, on Monday, reported the failed results from what should be the last Genasense clinical trial ever conducted. The combination of Genasense plus chemotherapy did not prolong the survival of skin cancer patients compared to treatment with chemotherapy alone.

And yes, it's another blow to the already troubled credibility of the therapeutic drug technology known as antisense, which attempts to make drugs out of snippets of genetic code that infiltrate cells and prevent the expression of harmful proteins.

Genta, Genasense, Warrell and I have a long history. I first tackled the subject in 2002 in a story that highlighted doubts and concerns about Genasense and its clinical trials. Many more bearish stories and columns followed. It's hard to imagine today, but Genta back then was a real company trading on the Nasdaq with significant institutional investor backing and a gaggle of sell-side analyst coverage. It was also a fantastically controversial stock that drew a ton of attention from some really smart biotech short-sellers who never believed in the Genasense story that Warrell pitched wherever he could find an audience.
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
DSCI $6.19 2.70%
EXEL $5.55 -0.18%
MNKD $3.82 3.50%
AAPL $109.19 -1.10%
FB $87.60 -0.62%


Chart of I:DJI
DOW 16,077.79 -296.97 -1.81%
S&P 500 1,917.91 -33.22 -1.70%
NASDAQ 4,675.4410 -58.0560 -1.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs